{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T17:49:14Z","timestamp":1768585754380,"version":"3.49.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T00:00:00Z","timestamp":1685491200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"NIH","award":["K08 HL148540"],"award-info":[{"award-number":["K08 HL148540"]}]},{"name":"NIH","award":["K08 HL153798"],"award-info":[{"award-number":["K08 HL153798"]}]},{"name":"NIH","award":["R01 HL83359"],"award-info":[{"award-number":["R01 HL83359"]}]},{"name":"NIH","award":["R01 HL149134"],"award-info":[{"award-number":["R01 HL149134"]}]},{"name":"NIH","award":["R01 HL162260"],"award-info":[{"award-number":["R01 HL162260"]}]},{"name":"NIH","award":["K23 HL145017"],"award-info":[{"award-number":["K23 HL145017"]}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["Career development award"],"award-info":[{"award-number":["Career development award"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["Career development award"],"award-info":[{"award-number":["Career development award"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","award":["Career development award"],"award-info":[{"award-number":["Career development award"]}],"id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"DOI":"10.1007\/s10840-023-01575-z","type":"journal-article","created":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T07:02:27Z","timestamp":1685516547000},"page":"111-118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors"],"prefix":"10.1007","volume":"67","author":[{"given":"Chen","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Fazal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Loh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ridhima","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sofia Elena","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shayena","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert J.","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjiv M.","family":"Narayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald M.","family":"Witteles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander C.","family":"Perino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"June-Wha","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0476-2972","authenticated-orcid":false,"given":"Tina","family":"Baykaner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,31]]},"reference":[{"key":"1575_CR1","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd.2018.21","volume":"17","author":"FM Ferguson","year":"2018","unstructured":"Ferguson FM, Gray NS. Kinase inhibitors: the road ahead. Nat Rev Drug Discov. 2018;17:353\u201377.","journal-title":"Nat Rev Drug Discov"},{"key":"1575_CR2","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1177\/1078155214561281","volume":"1","author":"C-S Lee","year":"2016","unstructured":"Lee C-S, Rattu MA, Kim SS. A review of a novel, Bruton\u2019s tyrosine kinase inhibitor, ibrutinib. J Oncol Pharm Pract. 2016;1:92\u2013104. https:\/\/doi.org\/10.1177\/1078155214561281.","journal-title":"J Oncol Pharm Pract."},{"key":"1575_CR3","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1016\/j.jacep.2018.06.004","volume":"12","author":"S Ganatra","year":"2018","unstructured":"Ganatra S, Sharma A, Shah S, Chaudhry GM, Martin DT, Neilan TG, et al. Ibrutinib-associated atrial fibrillation JACC Clin Electrophysiol. 2018;12:1491\u2013500. https:\/\/doi.org\/10.1016\/j.jacep.2018.06.004.","journal-title":"Ibrutinib-associated atrial fibrillation. JACC Clin Electrophysiol."},{"key":"1575_CR4","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1182\/bloodadvances.2017009720","volume":"1","author":"TE Wiczer","year":"2017","unstructured":"Wiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, et al. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. Blood Adv. 2017;1:1739\u201348.","journal-title":"Blood Adv"},{"issue":"18","key":"1575_CR5","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1016\/j.clml.2016.07.075","volume":"129","author":"B Lampson","year":"2016","unstructured":"Lampson B, Yu L, Barrientos J, Jacobsen E, Banerji V, Jones J, et al. Ventricular arrhythmias and sudden death in patients taking ibrutinib. Clin Lymphoma Myeloma Leuk. 2016;129(18):2581\u20134. https:\/\/doi.org\/10.1016\/j.clml.2016.07.075.","journal-title":"Clin Lymphoma Myeloma Leuk."},{"key":"1575_CR6","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","volume":"74","author":"J-E Salem","year":"2019","unstructured":"Salem J-E, Manouchehri A, Bretagne M, Lebrun-Vignes B, Groarke JD, Johnson DB, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74:1667\u201378.","journal-title":"J Am Coll Cardiol"},{"key":"1575_CR7","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.jacc.2018.06.002","volume":"72","author":"A Guha","year":"2018","unstructured":"Guha A, Derbala MH, Zhao Q, Wiczer TE, Woyach JA, Byrd JC, et al. Ventricular arrhythmias following ibrutinib initiation for lymphoid malignancies. J Am Coll Cardiol. 2018;72:697\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"1575_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s10840-022-01400-z","author":"M Fazal","year":"2022","unstructured":"Fazal M, Wei C, Chuy KL, Hussain K, Gomez SE, Ba SS, et al. Tyrosine kinase inhibitor-associated ventricular arrhythmias: a case series and review of literature. J Interv Card Electrophysiol. 2022. https:\/\/doi.org\/10.1007\/s10840-022-01400-z.","journal-title":"J Interv Card Electrophysiol"},{"key":"1575_CR9","doi-asserted-by":"publisher","first-page":"e001049","DOI":"10.1136\/openhrt-2019-001049","volume":"6","author":"F Baptiste","year":"2019","unstructured":"Baptiste F, Cautela J, Ancedy Y, Resseguier N, Aurran T, Farnault L, et al. High incidence of atrial fibrillation in patients treated with ibrutinib. Open Heart. 2019;6:e001049.","journal-title":"Open Heart"},{"key":"1575_CR10","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","volume":"17","author":"A Chanan-Khan","year":"2016","unstructured":"Chanan-Khan A, Cramer P, Demirkan F, Fraser G, Silva RS, Grosicki S, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17:200\u201311.","journal-title":"Lancet Oncol"},{"issue":"4","key":"1575_CR11","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.amjcard.2019.05.029","volume":"124","author":"MG Fradley","year":"2019","unstructured":"Fradley MG, Gliksman M, Emole J, Viganego F, Rhea I, Welter-Frost A, et al. Rates and risk of atrial arrhythmias in patients treated with ibrutinib compared with cytotoxic chemotherapy. Am J Card. 2019;124(4):539\u201344. https:\/\/doi.org\/10.1016\/j.amjcard.2019.05.029.","journal-title":"Am J Card."},{"key":"1575_CR12","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir T, Brown JR, O\u2019Brien S, Barrientos JC, Barr PM, Reddy NM, et al. Final analysis from RESONATE: up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353\u201363.","journal-title":"Am J Hematol"},{"key":"1575_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1400376","volume":"371","author":"JC Byrd","year":"2014","unstructured":"Byrd JC, Brown JR, O\u2019Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213\u201323.","journal-title":"N Engl J Med"},{"key":"1575_CR14","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425\u201337.","journal-title":"N Engl J Med"},{"key":"1575_CR15","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","volume":"6","author":"PM Barr","year":"2022","unstructured":"Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6:3440\u201350.","journal-title":"Blood Adv"},{"key":"1575_CR16","doi-asserted-by":"publisher","first-page":"3225","DOI":"10.2147\/DDDT.S377697","volume":"16","author":"R Dong","year":"2022","unstructured":"Dong R, Yan Y, Zeng X, Lin N, Tan B. Ibrutinib-associated cardiotoxicity: from the pharmaceutical to the clinical. Drug Des Devel Ther. 2022;16:3225\u201339.","journal-title":"Drug Des Devel Ther"},{"key":"1575_CR17","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1001\/jamaoncol.2014.218","volume":"1","author":"KJ Maddocks","year":"2015","unstructured":"Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, et al. Etiology of ibrutinib therapy discontinuation and outcomes in patients with chronic lymphocytic leukemia. JAMA Oncol. 2015;1:80\u20137.","journal-title":"JAMA Oncol"},{"key":"1575_CR18","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1182\/blood-2016-05-716977","volume":"128","author":"AR Mato","year":"2016","unstructured":"Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016;128:2199\u2013205.","journal-title":"Blood"},{"key":"1575_CR19","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/j.hrcr.2020.07.016","volume":"6","author":"A Prashar","year":"2020","unstructured":"Prashar A, Ilsar R, Roncolato F, Hopkins A. Recurrent ventricular fibrillation with different tyrosine kinase inhibitors for chronic myeloid leukemia. HeartRhythm Case Rep. 2020;6:770\u20133.","journal-title":"HeartRhythm Case Rep"},{"key":"1575_CR20","doi-asserted-by":"publisher","first-page":"758010","DOI":"10.3389\/fcvm.2021.758010","volume":"8","author":"M Cheng","year":"2021","unstructured":"Cheng M, Yang F, Liu J, Yang D, Zhang S, Yu Y, et al. Tyrosine kinase inhibitors-induced arrhythmias: from molecular mechanisms, pharmacokinetics to therapeutic strategies. Front Cardiovasc Med. 2021;8:758010.","journal-title":"Front Cardiovasc Med"},{"key":"1575_CR21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.ccep.2016.04.003","volume":"8","author":"JE Marine","year":"2016","unstructured":"Marine JE. Nonsustained ventricular tachycardia in the normal heart: risk stratification and management. Card Electrophysiol Clin. 2016;8:525\u201343.","journal-title":"Card Electrophysiol Clin"},{"key":"1575_CR22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, Jurczak W, Ka\u017amierczak M, Lamanna N, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319\u201332.","journal-title":"N Engl J Med"},{"key":"1575_CR23","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.jaccao.2020.11.016","volume":"3","author":"H Essa","year":"2021","unstructured":"Essa H, Lodhi T, Dobson R, Wright D, Lip GY. How to manage atrial fibrillation secondary to ibrutinib. JACC Cardio Oncol. 2021;3:140\u20134.","journal-title":"JACC Cardio Oncol"}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-023-01575-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10840-023-01575-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-023-01575-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T07:28:52Z","timestamp":1704439732000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10840-023-01575-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,31]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1]]}},"alternative-id":["1575"],"URL":"https:\/\/doi.org\/10.1007\/s10840-023-01575-z","relation":{},"ISSN":["1572-8595"],"issn-type":[{"value":"1572-8595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,31]]},"assertion":[{"value":"13 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The retrospective study protocol was approved by the Institutional Review Board of Stanford University. Approval number IRB-59813.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The authors declare no competing interests. Chen Wei, MD: None. Muhammad Fazal, MD: None. Alexander Loh: None. Ridhima Kapoor, MD: None. Sofia Gomez, MD: None. Shayena Shah, BA: None. Albert J. Rogers: National Institutes of Health grant K23 HL166977 and American Heart Association.Sanjiv M. Narayan, MD, PhD: Consulting fees from Abbott, TDK Incorporated and Beyond Limits.ai. Paul J. Wang, MD: None. Ronald Witteles, MD: Consulting fees from Pfizer, Alnylam, Eidos, Ionis, NovoNordisk, Intelia, and Janssen unrelated to this work. Alexander C. Perino: Research support from the American Heart Association, Pfizer Inc and Bristol Myers Squibb. Consultant for Abbott, Pfizer Inc and Bristol Myers Squibb.Paul Cheng, MD: National Institutes of Health grant K08 HL153798. T. Baykaner: Speaker and consultant fees from Biotronik, Medtronic and PaceMate unrelated to this work. June-Wha Rhee, MD: Sponsored research grant from Pfizer unrelated to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}